On May 26, 2022, Regulation (EU) 2017/746 on in vitro diagnostic medical devices officially enters into application across the European Union, introducing strict national language requirements for assay labels, IFUs, and Summaries of Safety and Performance (SSP).

Navigating the May 26, 2022 IVDR Milestone and Regulation (EU) 2022/112

Today, May 26, 2022, marks the official Date of Application of the EU In Vitro Diagnostic Medical Devices Regulation (IVDR, Regulation EU 2017/746). While Amending Regulation (EU) 2022/112—adopted in January 2022 to prevent supply shortages of essential laboratory tests—granted staggered transitional deadlines for legacy devices (extending to May 2025 for high-risk Class D devices, May 2026 for Class C, and May 2027 for Class B and sterile Class A), all new IVDs and non-sterile Class A devices placed on the EU market must comply immediately with full IVDR requirements.

Summaries of Safety and Performance (SSP) and Analytical Terminology

For Class C and Class D diagnostic devices, Article 29 of the IVDR requires manufacturers to draw up a Summary of Safety and Performance (SSP) validated by a Notified Body and made publicly available via EUDAMED in the official languages required by target Member States. Translating IVD documentation demands specialized biochemical and molecular diagnostics expertise—accurately rendering analytical sensitivity, limit of detection (LoD), cross-reactivity tables, and specimen stability warnings across up to 24 EU languages.

Avete bisogno di traduzioni multilingue certificate, asseverazioni legali o localizzazione conforme agli standard ISO per i vostri progetti internazionali? Richiedete un preventivo gratuito personalizzato ad Alphatrad e riceverete un piano operativo dettagliato entro 24 ore.